Genmab — December 2025
-
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes https://ir.genmab.com/news-releases/news-release-details/genmab-announces-closing-private-offering-senior-secured-notes
-
some agitation in the Dutch press about the extra-ordinary pay day for the Merus CEO - Topman Merus verdient $205 mln dankzij overname door Genmab https://fd.nl/financiele-markten/1579280/topman-merus-verdient-205-mln-dankzij-overname-door-genmab
-
Dec 4, 2025 9:45 AM EST
Citi 2025 Global Healthcare Conference https://ir.genmab.com/events-presentations -
RAINFOL-01 / Rina-S enlarged by ~200 patients, adding a few cohorts. a bit confusing, part H and J seem the same. maybe a different dosing schedule. They forgot the criteria for H. Interestingly cervical cancer is added.
https://clinicaltrials.gov/study/NCT05579366?tab=history&a=30&b=31&compareMode=sideBySide#version-content-panel -
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-multiple-clinical-trials-showing-treatment
-
Results from two arms of the EPCORE
NHL-2 trial, evaluating first-line, fixed-treatment duration epcoritamab in combination with chemotherapies, demonstrated overall response rates (ORR) of 93% (Arm 
and 98% (Arm 1) in patients with newly-diagnosed DLBCL, while a third arm (Arm 3) demonstrated a three-year overall survival (OS) rate of 96% in patients with FL following first-line combination treatment. -
Det er data som viser generelt høje responsrater, dybe og langvarige remissioner samt en håndterbar sikkerhedsprofil, især i udfordrende patientgrupper som ældre eller højrisikopatienter. Umiddelbart ser det ud til at epcoritamab på de fleste parametre giver baghjul til glofitamab og mosunetuzumab. Patientvenligheden med subkutan fixed-duration er et yderligere plus.
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind